Abstract
G250 or carbonic anhydrase IX (CA IX) is a membrane-associated carbonic anhydrase (CA) thought to play a role in the regulation of cell proliferation in response to hypoxic conditions and may be involved in oncogenesis and tumor progression. G250 refers to a monoclonal antibody (mAb) that was raised by immunization of mice with human renal cell carcinoma (RCC) homogenates. The RCC-associated transmembrane protein designated G250 has since proven to be identical to tumor-associated protein MN or CA IX. Previous studies using a mAb against CA IX have shown that CA IX is induced constitutively in certain tumor types, but is absent in most normal tissues with the exception of epithelial cells of the gastric mucosa. Furthermore, previous immunobiochemical studies of malignant and benign renal tissues revealed that CA IX was also highly expressed in RCC. Studies on tumor-bearing kidneys demonstrate selective uptake of mAb CA IX in antigen-positive cells versus antigen-negative cells. Furthermore, extraordinarily high uptake and the requirement of a low protein dose to obtain tumor saturation with respect to tumor targeting occur with mAb CA IX. These studies formed the basis of numerous clinical trials aimed at mAb-guided therapy in patients with metastatic RCC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Figlin RA: Renal cell carcinoma: management of advanced disease. J Urol 1999, 161:381–386.
Pantuck AJ, Zisman A, Belldegrun AS: The changing natural history of renal cell carcinoma. J Urol 2001, 166:1611–1623.
Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003, 30:843–852.
Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma. J Urol 2000, 163:408–417.
Pantuck AJ, Belldegrun AS, Figlin RA: Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma. N Engl J Med 2001, 345:1711–1712.
Flanigan RC, Salmon SE, Blumenstein BA, et al.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001, 345:1655–1659.
Mickisch GH, Garin A, van Poppe H, et al.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001, 358:966–970.
Oosterwijk E, Ruiter DJ, Hoedemaeker PJ, et al.: Monoclonal antibody G 250 recognizes a determinant present in renalcell carcinoma and absent from normal kidney. Int J Cancer 1986, 38:489–494.
Liao SY, Aurelio ON, Jan K, et al.: Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 1997, 57:2827–2831.
Pastorek J, Pastorekova S, Callebaut I, et al.: Cloning and characterization of MN, a human tumor-associated protein with a domain homologous to carbonic anhydrase and a putative helix-loop-helix DNA binding segment. Oncogene 1994, 9:2877–2888.
Opavsky R, Pastorekova S, Zelnik V, et al.: Human MN/CA9 gene, a novel member of the carbonic anhydrase family: structure and exon to protein domain relationships. Genomics 1996, 33:480–487.
Pastorekova S, Parkkila S, Parkkila AK, et al.: Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 1997, 112:398–408.
Gut MO, Parkkila S, Vernerova Z, et al.: Gastric hyperplasia in mice with targeted disruption of the carbonic anhydrase gene Car9. Gastroenterology 2002, 123:1889–1903.
Ivanov S, Liao SY, Ivanova A, et al.: Expression of hypoxiainducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 2001, 158:905–919.
Loncaster JA, Harris AL, Davidson SE, et al.: Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 2001, 61:6394–6399.
Wykoff CC, Beasley NJ, Watson PH, et al.: Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000, 60:7075–7083.
Harris AL: Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38–47.
Semenza GL: HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002, 8:S62–67. A comprehensive review on the role of hypoxia and the hypoxiainducible pathway in cancer progression and pathophysiology.
Ivanov SV, Kuzmin I, Wei MH, et al.: Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. Proc Natl Acad Sci U S A 1998, 95:12596–12601.
Potter C, Harris AL: Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 2004, 3:164–167.
Bui MH, Seligson D, Han KR, et al.: Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003, 9:802–811. This study demonstrated the prognostic significance of CA IX in kidney cancer. Decreased CA IX levels (<85%) were independently associated with poor survival in patients with advanced clear cell renal cell carcinoma.
Atkins M, McDermott D, Mier J, et al.: Carbonic anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy [abstract]. Proc ASCO 2004, 23:383.
Grabmaier K, MC AdW, Verhaegh GW, et al.: Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene 2004, 23:5624–5631. This study demonstrated that expression of CA IX was strictly regulated by HIF-1α in clear cell renal cell carcinoma.
Palapattu GS, Reiter RE: Monoclonal antibody therapy for genitourinary oncology: promise for the future. J Urol 2002, 168:2615–2623.
Kohler G, Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975, 256:495–497.
Zinkernagel RM, Hengartner H: Regulation of the immune response by antigen. Science 2001, 293:251–253.
Wang RF, Rosenberg SA: Human tumor antigens for cancer vaccine development. Immunol Rev 1999, 170:85–100. A comprehensive review on the discovery and current use of human tumor antigens for the development of cancer vaccines.
Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 1990, 50:814s-819s.
Ueda R, Shiku H, Pfreundschuh M, et al.: Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 1979, 150:564–579.
Lam JS, Belldegrun AS, Figlin RA: Advances in immune-based therapies of renal cell carcinoma. Expert Rev Anticancer Ther 2005, in press.
Oosterwijk E, Divgi CR, Brouwers A, et al.: Monoclonal antibody-based therapy for renal cell carcinoma. Urol Clin North Am 2003, 30:623–631.
Finstad CL, Cordon-Cardo C, Bander NH, et al.: Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proc Natl Acad Sci U S A 1985, 82:2955–2959.
Vessella RL, Moon TD, Chiou RK, et al.: Monoclonal antibodies to human renal cell carcinoma: recognition of shared and restricted tissue antigens. Cancer Res 1985, 45:6131–6139.
Grabmaier K, Vissers JL, De Weijert MC, et al.: Molecular cloning and immunogenicity of renal cell carcinoma-associated antigen G250. Int J Cancer 2000, 85:865–870.
Kranenborg MH, Boerman OC, de Weijert MC, et al.: The effect of antibody protein dose of anti-renal cell carcinoma monoclonal antibodies in nude mice with renal cell carcinoma xenografts. Cancer 1997, 80:2390–2397.
Steffens MG, Kranenborg MH, Boerman OC, et al.: Tumor retention of 186Re-MAG3, 111In-DTPA and 125I labeled monoclonal antibody G250 in nude mice with renal cell carcinoma xenografts. Cancer Biother Radiopharm 1998, 13:133–139.
van Dijk J, Oosterwijk E, van Kroonenburgh MJ, et al.: Perfusion of tumor-bearing kidneys as a model for scintigraphic screening of monoclonal antibodies. J Nucl Med 1988, 29:1078–1082.
van Dijk J, Uemura H, Beniers AJ, et al.: Therapeutic effects of monoclonal antibody G250, interferons and tumor necrosis factor, in mice with renal-cell carcinoma xenografts. Int J Cancer 1994, 56:262–268.
van Dijk J, Zegveld ST, Fleuren GJ, Warnaar SO: Localization of monoclonal antibody G250 and bispecific monoclonal antibody CD3/G250 in human renal-cell carcinoma xenografts: relative effects of size and affinity. Int J Cancer 1991, 48:738–743.
Oosterwijk E, Bander NH, Divgi CR, et al.: Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993, 11:738–750.
Divgi CR, Bander NH, Scott AM, et al.: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 1998, 4:2729–2739.
Steffens MG, Boerman OC, Oosterwijk-Wakka JC, et al.: Targeting of renal cell carcinoma with iodine-131-labeled chimeric monoclonal antibody G250. J Clin Oncol 1997, 15:1529–1537.
Steffens MG, Boerman OC, de Mulder PH, et al.: Phase I radioimmunotherapy of metastatic renal cell carcinoma with 131I-labeled chimeric monoclonal antibody G250. Clin Cancer Res 1999, 5:3268s-3274s.
Steffens MG, Oosterwijk-Wakka JC, Zegwaart-Hagemeier NE, et al.: Immunohistochemical analysis of tumor antigen saturation following injection of monoclonal antibody G250. Anticancer Res 1999, 19:1197–1200.
Steffens MG, Boerman OC, Oyen WJ, et al.: Intratumoral distribution of two consecutive injections of chimeric antibody G250 in primary renal cell carcinoma: implications for fractionated dose radioimmunotherapy. Cancer Res 1999, 59:1615–1619.
Brouwers AH, van Eerd JE, Frielink C, et al.: Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. J Nucl Med 2004, 45:327–337.
Divgi CR, O’Donoghue JA, Welt S, et al.: Phase I clinical trial with fractionated radioimmunotherapy using 131I-labeled chimeric G250 in metastatic renal cancer. J Nucl Med 2004, 45:1412–1421. These authors reported on the results of a phase I/II trial demonstrating the safety of 131I-chimeric G250 administered in high doses in patients with metastatic renal cell carcinoma.
Bleumer I, Knuth A, Oosterwijk E, et al.: A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004, 90:985–990. These authors reported on the results of a phase II trial demonstrating the tolerability of chimeric G250 antibody and a clinical benefit in 25% of patients with advanced renal cell carcinoma.
Liu Z, Smyth FE, Renner C, et al.: Anti-renal cell carcinoma chimeric antibody G250: cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 2002, 51:171–177.
Bevan P, Mala C, Kindler M, et al.: Results of a phase I/II study with monoclonal antibody CG250 in combination with IFNa-2A in metastatic renal cell carcinoma patients [abstract]. Proc ASCO 2004, 23:407.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lam, J.S., Pantuck, A.J., Belldegrun, A.S. et al. G250: A carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 7, 109–115 (2005). https://doi.org/10.1007/s11912-005-0036-7
Issue Date:
DOI: https://doi.org/10.1007/s11912-005-0036-7